Kura Oncology, Inc. — Form 10-Q Summary
Business context and reporting period
Quarterly report for the three months ended March 31, 2015. Kura is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for genetically defined solid tumors and blood cancers. Lead programs include tipifarnib, KO-947 and menin-MLL inhibitors. The March 2015 reverse merger with former public shell Zeta Acquisition Corp. III is accounted for as a reverse merger and capital transaction, with Prior Kura as the accounting acquirer.
Financial condition and operating metrics
| Metric | Three months ended March 31, 2015 |
|---|---|
| Product revenue | None; no approved products or product sales |
| Operating expenses | $4.688 million |
| Research and development | $3.628 million, including $1.024 million related-party expense |
| General and administrative | $1.060 million, including $23,000 related-party expense |
| Management fee income | $300,000 from related party |
| Net loss | $4.476 million |
| Basic and diluted loss per share | $1.41 |
| Cash used in operating activities | $4.123 million |
| Cash used in investing activities | $10,000 |
| Cash provided by financing activities | $56.580 million |
| Cash balance at March 31, 2015 | $53.571 million |
| Accumulated deficit | $8.147 million |
| Total liabilities | $5.922 million |
Gross margin and operating margin are not meaningful because the company had no product revenue. Cash increased from $1.124 million at December 31, 2014 to $53.571 million at March 31, 2015. The balance sheet showed no convertible notes payable at quarter-end because outstanding notes and accrued interest converted into common stock in connection with the financing. The filing states that existing cash was expected to fund requirements for the next twelve months, but substantial additional financing would be required thereafter.
Material changes versus the prior comparable period
- Prior Kura was incorporated in August 2014 and had no operations during the three months ended March 31, 2014; therefore, meaningful year-over-year comparisons are not available.
- Net cash increased substantially following the March 2015 financing. Kura received approximately $48.6 million of net common-stock proceeds after financing costs and reported $51.6 million of net common-stock proceeds in the cash flow statement.
- Convertible notes and accrued interest totaling approximately $7.6 million converted into common stock. The company also reported $5.0 million of convertible-note proceeds during the quarter.
- The March 2015 reverse merger resulted in the issuance of 14.508 million shares and left Prior Kura stockholders holding 100% of the combined company immediately after the transaction.
- Research and development spending reflected increased program activity, including approximately $500,000 of non-cash license fee expense and $644,000 of share-based compensation expense.
Guidance, outlook, risks and unusual items
- Management expected substantial research and development spending in 2015, including increased clinical development activities for tipifarnib and continued research on other programs.
- The company anticipated initiating a Phase 2 tipifarnib study in HRAS-mutated advanced solid tumors in the second quarter of 2015 and a Phase 2 study in peripheral T-cell lymphoma in the third quarter of 2015.
- KO-947 remained in IND-enabling preclinical development; other pipeline programs were at earlier stages.
- Management expected continued and increasing operating losses for the foreseeable future and had no committed external source of funds.
- Key risks include clinical-trial failure or delay, difficulty identifying and enrolling patients with specific genetic alterations, regulatory non-approval, dependence on third-party manufacturers and clinical research organizations, companion-diagnostic development, intellectual-property limitations and the need for additional capital.
- Tipifarnib composition-of-matter patents were expected to expire in 2016 in the United States and Europe, making method-of-use patents and regulatory exclusivity important to the commercial strategy.
- License agreements provided for potential development, regulatory and sales milestones of up to $81.7 million, plus tiered royalties; no milestones had been achieved as of March 31, 2015.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and effective disclosure controls at quarter-end.
Important facts for investors to verify
- Reconcile the financing proceeds reported in the balance sheet, cash flow statement and MD&A, including approximately $3.7 million of financing costs.
- Confirm the post-merger share count, including 14.508 million shares outstanding as of May 11, 2015 and approximately 4.191 million unvested shares subject to repurchase at March 31, 2015.
- Monitor cash burn, clinical spending and the timing and terms of future financing required after the company’s stated twelve-month cash runway.
- Verify the initiation, enrollment and results of the planned Phase 2 tipifarnib trials and the progress of KO-947 and menin-MLL programs.
- Review the Janssen and other license agreements for diligence obligations, patent rights, milestones, royalties and termination provisions.
- Assess the impact of tipifarnib patent expirations, potential generic competition and the need for companion-diagnostic approvals.